Salivary Gland Neoplasm

cancer family

Identifier: CI-CAN-00000343
Entity page: /cancer/salivary-gland-neoplasm ↗
Edges: 400

Neighbours: 15 genes41 drugs10 trials
Drawn: 60 of 66 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Salivary Gland Neoplasm investigated for …INVESTIGATED_FOR35 of 35show fewer
← investigated for	Triptorelinother	unknown	2	Salivary Gland Neoplasm	1	Curated	chembl	graph →
← investigated for	Trastuzumab Emtansineadc	unknown	2

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ERBB2 Amplification Pertuzumab1 active / 1 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Salivary Gland Carcinoma
ERBB2 Amplification Trastuzumab2 active / 4 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Salivary Gland Carcinoma
ERBB2 Overexpression Trastuzumab2 active / 4 trials
Curatedlevel Csensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Malignant Salivary Gland Neoplasm
FGFR2 S252W Erdafitinib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedFGFR2 altered in 2.9% (30 / 1,049 cases)no approval record in this cancercontext: Salivary Gland Adenoid Cystic Carcinoma
ALK Fusion Alectinib0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ALK in this cancerno approval record in this cancercontext: Pancreatic Acinar Cell Carcinoma
ERBB2 Overexpression Capecitabine0 active / 2 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Malignant Salivary Gland Neoplasm
ERBB2 Overexpression Paclitaxel0 active / 4 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Malignant Salivary Gland Neoplasm
ERBB2 Overexpression Zoledronic Acid0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Malignant Salivary Gland Neoplasm

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Salivary Gland Neoplasm altered in cohorts of …ALTERED_INderived15 of 17show all (up to 200)
← altered in cohorts of	NOTCH1 232 / 1,049 cases (22 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	KDM6A 138 / 1,049 cases (13 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ARID1A 120 / 1,049 cases (11 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	KMT2D 111 / 1,049 cases (11 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	BCOR 109 / 1,049 cases (10 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	KMT2C 99 / 1,049 cases (9.4 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CREBBP 98 / 1,049 cases (9.3 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ARID1B 82 / 1,049 cases (7.8 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TERT 82 / 1,049 cases (7.8 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TP53 76 / 1,049 cases (7.2 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	EP300 74 / 1,049 cases (7.1 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	RUNX1 71 / 1,049 cases (6.8 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SPEN 67 / 1,049 cases (6.4 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	BRCA2 64 / 1,049 cases (6.1 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ATM 59 / 1,049 cases (5.6 %) · ssm · acc_2019	—	—	Adenoid Cystic Carcinoma	1	Observed	cbioportal	graph →

Salivary Gland Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 81show all (up to 200)
→ investigated in trials for	Cetuximabmonoclonal_antibody 11 trials (0 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 11 trials (8 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall_molecule 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall_molecule 9 trials (4 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinib Hydrochloridesmall_molecule 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall_molecule 7 trials (3 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 7 trials (3 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall_molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 5 trials (0 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal_antibody 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Salivary Gland Neoplasm	4	Observed	clinicaltrials	graph →

Salivary Gland Neoplasm studied in …STUDIED_INderived10 of 267show all (up to 200)
→ studied in	NCT07667400Phase 1/Phase 2 · not yet recruiting Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped ALIAS · 267 trials mapped (86 active)	—	—	Malignant Salivary Gland Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07845097Phase 2 · not yet recruiting Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Adenoid Cystic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04325828Phase 2 · active not recruiting A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Salivary Gland Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04858334Phase 2 · recruiting APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Pancreatic Acinar Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ALIAS · 267 trials mapped (86 active)	—	—	Malignant Salivary Gland Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06781567Phase 2 · recruiting Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Adenoid Cystic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07162480Phase 2 · recruiting Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Adenoid Cystic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06462183Phase 1 · active not recruiting Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Adenoid Cystic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04140526Phase 1/Phase 2 · active not recruiting Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Adenoid Cystic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07815522Phase 2 · recruiting Abiraterone With Dalpiciclib in Salivary Gland Carcinoma · condition mapped ONTOLOGY_EXACT · 267 trials mapped (86 active)	—	—	Salivary Gland Carcinoma	1	Observed	clinicaltrials	graph →